Microbial transformation of pentacyclic triterpenes for anti-inflammatory agents on the HMGB1 stimulated RAW 264.7 cells by Streptomyces olivaceus CICC 23628
Indirect anodic oxidation of soyasapogenol B (3β, 22β, 24-trihydroxyolean-12-ene) was carried out using KI as a mediator in t-BuOH-H2O solution, so that the 3-ketone derivative was obtained as the only oxidation product in a favorable yield. As a result of application to various polyhydroxylated triterpenes, selective electrochemical oxidation was shown to occur in the C-3 hydroxyl group of the polyhydroxyl triterpenes with the C-24 hydroxyl group. The reaction pathway is discussed.
The crystalline main saponin “Aescin” from the seeds of Aesculus hippocastanum L, is a complex mixture, the individual components of which have the same basic principle. A highly hydroxylated triterpene derivative is present (protoaescigenin and barringtogenol C) in which angelic/tiglic acid and acetic acid are bound as esters at C-21 and C-22. The OH group at C-3 is linked to d-glucuronic acid with
[EN] PREPARATION OF PROTOESCIGENIN FROM ESCIN<br/>[FR] ÉLABORATION DE PROTOESCIGÉNINE À PARTIR D'ESCINE
申请人:INST FARMACEUTYCZNY
公开号:WO2013055244A1
公开(公告)日:2013-04-18
The invention relates to the process for preparation of protoescigenin from escin isolated from Aesculum hippocastanum. The process comprises the following steps: two-step hydrolysis under acidic and basic conditions, enrichment of the crude mixture of sapogenins with protoescigenin, isolation of the mixture of sapogenins in a solid form, purification of the obtained solid and isolation of high purity protoescigenin. The present invention also relates to protoescigenin monohydrate in a crystalline form and the preparation thereof. Protoescigenin is a polyhydroxyl aglycone, which can be used as the synthon in the chemical modifications of naturally occurring saponis.
Polynucleotide binding complexes comprising sterols and saponin
申请人:Nordic Vaccine Technology A/S
公开号:EP2011517A1
公开(公告)日:2009-01-07
The present invention pertains to complexes comprising sterols and saponins. The complexes are capable of binding a genetic determinant including a polynucleotide. The complexes may further comprise a lipophilic moiety, optionally a lipophilic moiety comprising a contacting group and/or a targeting ligand, and/or a saccharide moiety. The complexes may further comprise an immunogenic determinant and/or an antigenic determinant and/or a medicament and/or a diagnostic compound. The complexes may in even further embodiments be encapsulated by an encapsulation agent including a biodegradable microsphere. The present invention also pertains to pharmaceutical compositions and methods of treatment of an individual by therapy and/or surgery, methods of cosmetic treatment, and diagnostic methods practised on the human or animal body.